Экономическая эффективность доклинической диагностики болезни Паркинсона: марковская модель

Cost-effectiveness of preclinical Parkinsonism diagnosis: a Markov model

Sergey Vartanov (sergvart@gmail.com), Irina Bogatova, Irina Denisova, Valerian Kucheryanu, Natalia Tourdyeva, Tatyana Chubarova, Marina Shakleina and Victor Polterovich
Authors registered in the RePEc Author Service: Виктор Меерович Полтерович and Natalia Turdyeva

MPRA Paper from University Library of Munich, Germany

Abstract: This work is devoted to the pharmacoeconomic analysis of the results of the introduction of early (preclinical) diagnosis of Parkinson's disease in Russia. On the basis of a combination of socio-economic determinants and a panel of blood biomarkers, it may be possible to identify among the entire population a “risk group” - people most likely to develop parkinsonism or are already sick with it at the preclinical stage. Together with the approach traditionally used in the pharmacoeconomics of chronic and long-term diseases, based on the representation of the dynamics of the development of the disease using Markov chains - discrete random processes without memory - this makes it possible to analyze the economic effects of early detection of cases and conducting preventive preclinical therapy. The work investigated the Markov model of Parkinson's disease, consisting of nine states - five states corresponding to the stages HY1-HY5, two preclinical states ("risk group", "prodromal state"). Using as the initial data for the model, the probability of transition between states and health-adjusted quality of life (HRQoL) estimates, published in a number of works of researchers affiliated with AbbVie Corporation, and calculating the cost of therapy based on open data on the cost of drugs and procedures in Russian market (eapteka, apteka.ru, piluli.ru, website of the Ministry of Health of the Russian Federation), the work shows that due to the introduction of preclinical diagnostics and preventive treatment at preclinical stages, identified patients can significantly increase the average survival time (in quality of life-adjusted years) compared to standard therapy, and the average cost per patient until the end of life can be significantly reduced.

Keywords: Markov chain with discrete time; Markov model; Parkinson disease; pharmacoeconomics (search for similar items in EconPapers)
JEL-codes: C02 C63 C65 I10 I11 I19 (search for similar items in EconPapers)
Date: 2020-09
New Economics Papers: this item is included in nep-cis
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://mpra.ub.uni-muenchen.de/103096/1/MPRA_paper_103096.pdf original version (application/pdf)
https://mpra.ub.uni-muenchen.de/103098/8/MPRA_paper_103098.pdf revised version (application/pdf)
https://mpra.ub.uni-muenchen.de/103218/8/MPRA_paper_103098.pdf revised version (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pra:mprapa:103096

Access Statistics for this paper

More papers in MPRA Paper from University Library of Munich, Germany Ludwigstraße 33, D-80539 Munich, Germany. Contact information at EDIRC.
Bibliographic data for series maintained by Joachim Winter (winter@lmu.de).